Compare TLPH & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLPH | KZIA |
|---|---|---|
| Founded | 2005 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.5M | 125.6M |
| IPO Year | 2010 | 2002 |
| Metric | TLPH | KZIA |
|---|---|---|
| Price | $0.80 | $4.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $3.13 | ★ $27.60 |
| AVG Volume (30 Days) | 160.2K | ★ 251.4K |
| Earning Date | 11-12-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,151,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $4.86 |
| 52 Week High | $1.57 | $17.40 |
| Indicator | TLPH | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 31.24 | 23.06 |
| Support Level | $0.74 | N/A |
| Resistance Level | $0.89 | $14.85 |
| Average True Range (ATR) | 0.09 | 0.69 |
| MACD | -0.03 | -0.20 |
| Stochastic Oscillator | 18.41 | 4.69 |
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.